Early Prediction Study of Linezolid-Induced Thrombocytopenia Based on Metabolomics and Population Pharmacokinetics

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400079613

Enrollment

Unknown

Registered

2024-01-08

Start date

2024-01-15

Completion date

Unknown

Last updated

2024-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection

Interventions

Observation group:No special interventions

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1.Inpatients at our hospital receiving linezolid treatment, 2.Aged = 18 years, 3.Linezolid intravenous infusion treatment for =2 days, 4.Receiving therapeutic drug monitoring at least once during the treatment period.

Exclusion criteria

Exclusion criteria: 1.Patients with incomplete clinical data and medication history or those who did not undergo regular platelet monitoring during the follow-up period, 2.Pregnant or breastfeeding patients, 3.Patients with trauma, major bleeding, or undergoing surgical treatment, 4.Patients with abnormally low (400×10^9/L) platelet counts before using linezolid, 5.Blood samples from patients who have already developed thrombocytopenia.

Design outcomes

Primary

Measure	Time frame
Serum concentration of linezolid;Platelet count;	—

Countries

China

Contacts

Public ContactHuaijun Zhu

Nanjing Drum Tower Hospital

huaijun.zhu@gmail.com+86 137 7667 2178

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026